Evidence map›Paper›PMID 22028782›Full record

ArticlePloS one2011

The role of atypical protein kinase C in CSF-1-dependent Erk activation and proliferation in myeloid progenitors and macrophages.

Angel W Lee

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. CSF-1 receptor signaling in myeloid cells.Cold Spring Harbor perspectives in biology · 2014
    Review
  8. Article
  9. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.Medical oncology (Northwood, London, England) · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Angel W LeeDepartment of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, United States of America. awmlee@angelleelab.org
The University of Texas Health Science Center at Houston · US

Funding

MECHANISM OF CSF 1 RECEPTOR GROWTH, SURVIVAL PROMOTIONR01CA085368 · NCI · WASHINGTON UNIVERSITY · PI LEE, ANGEL W · 2001 to 2004
$1.0M
NCI NIH HHS R01 CA085368NCI NIH HHS R01-CA85368
6 · The paper itself

Abstract

Colony stimulating factor-1 (CSF-1 or M-CSF) is the major physiological regulator of the proliferation, differentiation and survival of cells of the mononuclear phagocyte lineage. CSF-1 binds to a receptor tyrosine kinase, the CSF-1 receptor (CSF-1R). Multiple pathways are activated downstream of the CSF-1R; however, it is not clear which pathways regulate proliferation and survival. Here, we investigated the role of atypical protein kinase Cs (PKCζ) in a myeloid progenitor cell line that expressed CSF-1R (32D.R) and in primary murine bone marrow derived macrophages (BMMs). In 32D.R cells, CSF-1 induced the phosphorylation of PKCζ and increased its kinase activity. PKC inhibitors and transfections with mutant PKCs showed that optimal CSF-1-dependent Erk activation and proliferation depended on the activity of PKCζ. We previously reported that CSF-1 activated the Erk pathway through an A-Raf-dependent and an A-Raf independent pathway (Lee and States, Mol. Cell. Biol.18, 6779). PKC inhibitors did not affect CSF-1 induced Ras and A-Raf activity but markedly reduced MEK and Erk activity, implying that PKCζ regulated the CSF-1-Erk pathway at the level of MEK. PKCζ has been implicated in activating the NF-κB pathway. However, CSF-1 promoted proliferation in an NF-κB independent manner. We established stable 32D.R cell lines that overexpressed PKCζ. Overexpression of PKCζ increased the intensity and duration of CSF-1 induced Erk activity and rendered cells more responsive to CSF-1 mediated proliferation. In contrast to 32D.R cells, PKCζ inhibition in BMMs had only a modest effect on proliferation. Moreover, PKCζ -specific and pan-PKC inhibitors induced a paradoxical increase in MEK-Erk phosphorylation suggesting that PKCs targeted a common negative regulatory step upstream of MEK. Our results demonstrated that CSF-1 dependent Erk activation and proliferation are regulated differentially in progenitors and differentiated cells.

Indexed as

AnimalsBone Marrow CellsCell LineCell ProliferationEnzyme ActivationExtracellular Signal-Regulated MAP KinasesHumansMacrophage Colony-Stimulating FactorMacrophagesMAP Kinase Signaling SystemMiceMitosisMyeloid Progenitor CellsNF-kappa BPhosphorylationProtein Kinase CExtracellular Signal-Regulated MAP KinasesMacrophage Colony-Stimulating FactorNF-kappa Bphorbolol myristate acetatePKC-3 proteinProtein Kinase CProtein Kinase InhibitorsProto-Oncogene Proteins A-rafProto-Oncogene Proteins c-rafTetradecanoylphorbol AcetateTumor Necrosis Factor-alpha

Identifiers

PMID22028782
PMCPMC3196503
OpenAlexW2074990743

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.